[
Effective January 1, 2017, AmeriHealth Pennsylvania will update its
list of specialty drugs that require member
cost-sharing (e.g., copayment, deductible, and coinsurance). Cost-sharing
applies to select medical benefit specialty
drugs for members who are enrolled in Commercial FLEX products and other select
plans. The member?s cost-sharing
amount is based on the terms of the member?s benefit contract. Individual
benefits should be verified.
The updated list will include approximately 130 drugs, including new
additions for Cinqair® (reslizumab), InflectraTM
(infliximab)*, Nucala® (mepolizumab), and
Probuphine® (buprenorphine).
The updated list is available on our website. The current 2016 cost-sharing list
can be accessed through this link until December 31, 2016.
* For members enrolled in Commercial FLEX products,
cost-sharing applies to all biosimilars of infliximab approved by the U.S. Food
and
Drug Administration.
]